Ticker brief
ALEC ALECTOR INC
Consumer, Non-cyclical · Biotechnology
last close
$1.83
1 day
+0.0%
14 days
-12.0%
mkt cap
·
signals 14d
29
authors 14d
18
crowd 14d
+1.0σ
Sentiment — last 14 days
daily mean sentiment, 2026-10-05 → 2026-10-16 · now +0.28 (−1 bearish … +1 bullish)
Who spoke18
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @Greatstockpix | C | -1.40 | 3 | +0.27 |
| @DekmarTrades | C | -0.59 | 3 | +0.37 |
| @DavidScottAdams | C | -2.62 | 3 | +0.52 |
| @Tickeron | C | +1.53 | 3 | +0.48 |
| @Briefingcom | B | -2.26 | 2 | +0.59 |
| @BiopharmIQ | B | · | 2 | +0.38 |
| @Analytica_X | B | -0.29 | 2 | +0.20 |
| @AlertsAndNews | C | -3.92 | 1 | +0.50 |
| @OpenOutcrier | C | · | 1 | +0.65 |
| @OTR444 | C | +0.13 | 1 | +0.50 |
| @abc51648039 | C | -0.96 | 1 | +0.30 |
| @FierceBiotech | A | -0.83 | 1 | +0.60 |
| @OptionsFlowBoss | C | · | 1 | +0.50 |
| @fwpharma | B | -1.91 | 1 | +0.45 |
| @OzmosiHealth | C | · | 1 | +0.00 |
| @cnfinancewatch | B | -1.23 | 1 | +0.30 |
| @newsinvesting | C | · | 1 | +0.10 |
| @BiotechCH | B | +1.42 | 1 | +0.45 |
Recent signals29of 29 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @BiotechCH | +0.45 | Preclinical data show 75%-80% tau mRNA knockdown and support interest in ALEC's BBB approach. | -0.5% | tweet ↗ |
| 2026-10-16 | @newsinvesting | +0.10 | Alector announces a $75M underwritten offering priced above the prior close. | -0.5% | tweet ↗ |
| 2026-10-16 | @cnfinancewatch | +0.30 | Quant screen ranks breakout, base and high-profit-positioning candidates without explicit entry intent. | -0.5% | tweet ↗ |
| 2026-10-09 | @BiopharmIQ | +0.35 | Weekly biotech event roundup covering acquisition, clinical data, FDA status, licensing, and a trial miss. | -12.0% | tweet ↗ |
| 2026-10-08 | @OzmosiHealth | +0.00 | Company announced a dated neurodegenerative-disease results presentation. | -9.4% | tweet ↗ |
| 2026-10-06 | @Analytica_X | +0.40 | Alector announced a Roche/Genentech deal worth up to $1.27B, with $100M upfront. | +1.1% | tweet ↗ |
| 2026-10-06 | @Analytica_X | +0.00 | Reports extreme volume in ALEC and SDEV, with SDEV down 47%. | +1.1% | tweet ↗ |
| 2026-10-05 | @Tickeron | +0.55 | Alector signed an exclusive Genentech license worth $100M upfront and up to $1.17B. | -8.0% | tweet ↗ |
| 2026-10-05 | @fwpharma | +0.45 | Roche licensed Alector's Parkinson's therapy in a deal worth up to $1.3B | -8.0% | tweet ↗ |
| 2026-10-05 | @DavidScottAdams | +0.70 | Expects further bullish momentum in these names on Tuesday. — Explicitly forecasts more upside momentum for the listed names next session. | -8.0% | tweet ↗ |
| 2026-10-05 | @Tickeron | +0.35 | Four analyst targets average $3.60, implying large but disputed upside. | -8.0% | tweet ↗ |
| 2026-10-05 | @Tickeron | +0.55 | Alector announced an exclusive Genentech licensing agreement with major economics. | -8.0% | tweet ↗ |
| 2026-10-05 | @OptionsFlowBoss | +0.50 | Lists unusually bullish options-volume multiples midday. | -8.0% | tweet ↗ |
| 2026-10-05 | @FierceBiotech | +0.60 | Reports Genentech paying Alector $100M upfront for exclusive drug rights. | -8.0% | tweet ↗ |
| 2026-10-05 | @BiopharmIQ | +0.40 | Premarket biotech-mover list pairs six leading gains with their stated catalysts. | -8.0% | tweet ↗ |
| 2026-10-05 | @DavidScottAdams | +0.55 | Recaps a team entry below $2.10 and a rebound from the lows. | -8.0% | tweet ↗ |
| 2026-10-05 | @DekmarTrades | +0.60 | Flags a squeeze setup requiring a break above $3 after a licensing agreement. | -8.0% | tweet ↗ |
| 2026-10-05 | @DavidScottAdams | +0.30 | Identifies the listed stocks as morning movers. | -8.0% | tweet ↗ |
| 2026-10-05 | @abc51648039 | +0.30 | Provides ALEC breakout, resistance and support levels without explicit entry intent. | -8.0% | tweet ↗ |
| 2026-10-05 | @Greatstockpix | +0.00 | Updated morning gapper watchlist without entries or directional calls; first six unique tickers retained. | -8.0% | tweet ↗ |
| 2026-10-05 | @OTR444 | +0.50 | Momentum watchlist cites listings, agreements, trial results and deal catalysts. | -8.0% | tweet ↗ |
| 2026-10-05 | @OpenOutcrier | +0.65 | Alector entered a global license agreement with Genentech for a Parkinson's and neurodegeneration therapy. | -8.0% | tweet ↗ |
| 2026-10-05 | @DekmarTrades | +0.00 | Names three morning stocks with news but provides no event details. | -8.0% | tweet ↗ |
| 2026-10-05 | @AlertsAndNews | +0.50 | Alector granted Genentech exclusive AL050 rights for $100M upfront and up to $1.17B in milestones. | -8.0% | tweet ↗ |
| 2026-10-05 | @Briefingcom | +0.60 | Alector licensed AL050 to Genentech for $100M upfront and up to $1.17B in milestones. | -8.0% | tweet ↗ |
| 2026-10-05 | @Briefingcom | +0.58 | Lists premarket gap moves, led by ALEC and PCVX higher and CHRW lower. | -8.0% | tweet ↗ |
| 2026-10-05 | @DekmarTrades | +0.50 | Alector enters a global licensing agreement with Genentech for an investigational therapy. | -8.0% | tweet ↗ |
| 2026-10-05 | @Greatstockpix | +0.20 | Lists five premarket gappers for monitoring. | -8.0% | tweet ↗ |
| 2026-10-05 | @Greatstockpix | +0.60 | Alector licenses AL050 to Genentech for $100 million upfront and up to $1.17 billion in milestones. | -8.0% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.